ArticleCell stem cell2013
Reprogramming of human fibroblasts to pluripotency with lineage specifiers.
Article in Cell stem cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 149 citations in OpenAlex.
- PUS7 pseudouridylation of 7SK orchestrates human somatic cell reprogramming into iPS cells.Nature chemical biology · 2026Article
- Article
- Generation and Characterization of Patient-Derived Human Pluripotent Stem Cell Lines for Retinal Gene Therapy.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Cell-type-specific functionality encoded within the intrinsically disordered regions of OCT4.Nature communications · 2025Article
- Opposing lineage specifiers induce a protumor hybrid identity state in lung adenocarcinoma.Genes & development · 2025Article
- Molecular basis of cell fate plasticity - insights from the privileged cells.Current opinion in genetics & development · 2025Review
- The self-renewal function of Oct-4 can be replaced by the EWS-Oct-4 fusion protein in embryonic stem cells.Cellular and molecular life sciences : CMLS · 2025Article
- The regulatory architecture of the primed pluripotent cell state.Nature communications · 2025Article
- Cell reprogramming: methods, mechanisms and applications.Cell regeneration (London, England) · 2025Review
- Optimized Prime Editing of Human Induced Pluripotent Stem Cells to Efficiently Generate Isogenic Models of Mendelian Diseases.International journal of molecular sciences · 2024Article
- Manipulating cell fate through reprogramming: approaches and applications.Development (Cambridge, England) · 2024Review
- Synthetic genetic circuits to uncover the OCT4 trajectories of successful reprogramming of human fibroblasts.Science advances · 2023Article
- Pluripotency-independent induction of human trophoblast stem cells from fibroblasts.Nature communications · 2023Article
- USP7 represses lineage differentiation genes in mouse embryonic stem cells by both catalytic and noncatalytic activities.Science advances · 2023Article
- Epigenetics, ovarian cell plasticity, and platelet-rich plasma: Mechanistic theories.Reproduction & fertility · 2022Article
- Toward in Vitro Production of Platelet from Induced Pluripotent Stem Cells.Stem cell reviews and reports · 2022Review
- Advances in RNA Viral Vector Technology to Reprogram Somatic Cells: The Paramyxovirus Wave.Molecular diagnosis & therapy · 2022Review
- The functional diversity of the POUV-class proteins across vertebrates.Open biology · 2022Review
- OCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease.NPJ Regenerative medicine · 2022Article
- Directed Evolution of an Enhanced POU Reprogramming Factor for Cell Fate Engineering.Molecular biology and evolution · 2021Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the initial discovery that OCT4, SOX2, KLF4, and c-MYC overexpression sufficed for the induction of pluripotency in somatic cells, methodologies replacing the original factors have enhanced our understanding of the reprogramming process. However, unlike in mouse, OCT4 has not been replaced successfully during reprogramming of human cells. Here we report on a strategy to accomplish this replacement. Through a combination of transcriptome and bioinformatic analysis we have identified factors previously characterized as being lineage specifiers that are able to replace OCT4 and SOX2 in the reprogramming of human fibroblasts. Our results show that it is possible to replace OCT4 and SOX2 simultaneously with alternative lineage specifiers in the reprogramming of human cells. At a broader level, they also support a model in which counteracting lineage specification networks underlies the induction of pluripotency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.